SEC Form 3 · accession 0000905718-16-001595

Celldex Therapeutics, Inc. · CLDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Chief Product Dev Officer

Period of report

Aug 10, 2016

Accepted (ET)

Aug 12, 2016 · 7:58 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000744218

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common stock, par value $0.001 per share	holding	—	—		—	7,322	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1	$4.50	holding	—	—	—	—	Jan 21, 2020	Common Stock	20,000	—	D
Employee Stock Option (right to buy)^F2	$2.80	holding	—	—	—	—	Aug 5, 2021	Common Stock	15,000	—	D
Employee Stock Option (right to buy)^F3	$6.37	holding	—	—	—	—	Sep 20, 2022	Common Stock	30,000	—	D
Employee Stock Option (right to buy)^F4	$16.36	holding	—	—	—	—	Jul 1, 2023	Common Stock	30,000	—	D
Employee Stock Option (right to buy)^F5	$13.45	holding	—	—	—	—	Jun 4, 2024	Common Stock	31,000	—	D
Employee Stock Option (right to buy)^F6	$25.41	holding	—	—	—	—	Jun 10, 2025	Common Stock	75,000	—	D
Employee Stock Option (right to buy)^F7	$4.72	holding	—	—	—	—	Jun 8, 2026	Common Stock	81,000	—	D

F1The option became exercisable as to 25% of the shares on 1/21/2011 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
F2The option became exercisable as to 25% of the shares on 8/5/2012 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
F3The option became exercisable as to 25% of the shares on 9/20/2013 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F4The option became exercisable as to 25% of the shares on 7/1/2014 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5The option became exercisable as to 25% of the shares on 6/4/2015 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F6The option became exercisable as to 25% of the shares on 6/10/2016 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F7The option becomes exercisable as to 25% of the shares on 6/8/2017 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.